全文获取类型
收费全文 | 4442篇 |
免费 | 569篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 42篇 |
儿科学 | 110篇 |
妇产科学 | 92篇 |
基础医学 | 730篇 |
口腔科学 | 31篇 |
临床医学 | 1086篇 |
内科学 | 672篇 |
皮肤病学 | 59篇 |
神经病学 | 443篇 |
特种医学 | 196篇 |
外科学 | 645篇 |
综合类 | 75篇 |
一般理论 | 1篇 |
预防医学 | 353篇 |
眼科学 | 35篇 |
药学 | 308篇 |
中国医学 | 1篇 |
肿瘤学 | 141篇 |
出版年
2023年 | 72篇 |
2022年 | 28篇 |
2021年 | 67篇 |
2020年 | 56篇 |
2019年 | 52篇 |
2018年 | 121篇 |
2017年 | 126篇 |
2016年 | 148篇 |
2015年 | 133篇 |
2014年 | 148篇 |
2013年 | 170篇 |
2012年 | 184篇 |
2011年 | 199篇 |
2010年 | 154篇 |
2009年 | 159篇 |
2008年 | 183篇 |
2007年 | 180篇 |
2006年 | 152篇 |
2005年 | 139篇 |
2004年 | 121篇 |
2003年 | 149篇 |
2002年 | 133篇 |
2001年 | 125篇 |
2000年 | 142篇 |
1999年 | 130篇 |
1998年 | 63篇 |
1997年 | 77篇 |
1996年 | 64篇 |
1995年 | 60篇 |
1994年 | 52篇 |
1993年 | 31篇 |
1992年 | 78篇 |
1991年 | 73篇 |
1990年 | 63篇 |
1989年 | 65篇 |
1988年 | 67篇 |
1987年 | 75篇 |
1986年 | 69篇 |
1985年 | 65篇 |
1984年 | 45篇 |
1983年 | 40篇 |
1982年 | 39篇 |
1981年 | 28篇 |
1979年 | 32篇 |
1977年 | 26篇 |
1976年 | 28篇 |
1974年 | 26篇 |
1973年 | 33篇 |
1972年 | 28篇 |
1970年 | 25篇 |
排序方式: 共有5020条查询结果,搜索用时 15 毫秒
101.
E Bonda M Petrides S Frey A Evans 《Proceedings of the National Academy of Sciences of the United States of America》1995,92(24):11180-11184
Regional cerebral blood flow was measured with positron emission tomography in human subjects during the performance of a task requiring mental rotation of their hand and a perceptually equivalent control task that did not require such a process. Comparison of the distribution of cerebral activity between these conditions demonstrated significant blood flow increases in the superior parietal cortex, the intraparietal sulcus, and the adjacent rostralmost part of the inferior parietal lobule. These findings demonstrated that, in the human brain, there is a specific system of parietal areas that are involved in mental transformations of the body-in-space. 相似文献
102.
Impact of recipient ABH secretor status on outcome in minor ABO‐incompatible hematopoietic stem cell transplantation 下载免费PDF全文
103.
Charbonneau TT Wade NA Weiner L Omene J Frenkel L Wethers JA Arpadi S Bamji M Frey HM Gupta A Conroy JM 《AIDS patient care and STDs》1997,11(4):227-236
Infants (n = 313) of HIV-infected mothers were enrolled (mean age 1.9 weeks, range 0-8 weeks) in a 3-year prospective study of vertical transmission. Fifty-six infants (17.9%) had laboratory and clinical evidence of HIV infection. Polymerase chain reaction (PCR) provided early and reliable identification of infected infants. Thirty-one of the 56 infected infants had specimens submitted when the infants were 4 weeks of age or less and 30 (97%) tested PCR positive. This percentage increased to 100% by 8 weeks of age when 51 of the 56 infected infants had specimens tested for that time period. Immune complex dissociation (ICD) antigen testing was a sensitive method for diagnosis of infection but only in infants older than 1 month. p24 antigen testing, although free of false positives, is less sensitive than either of the other methods. Among surrogate markers of HIV infection, elevation of soluble CD8 levels precedes an increase in immunoglobulin levels or a decline in CD4 T lymphocytes. Vertical transmission is significantly lower in Central and Western New York State than other regions. Transmission is significantly higher in low birthweight babies and in infants whose mothers have CD4 counts < 500. This study provided the basis for establishing a Pediatric HIV PCR Testing Service for the early diagnosis of HIV infection in neonates. 相似文献
104.
105.
106.
107.
Sheena G Sullivan Sandra Carlson Allen C Cheng Monique BN Chilver Dominic E Dwyer Melissa Irwin Jen Kok Kristine Macartney Jennifer MacLachlan Cara Minney-Smith David Smith Nigel Stocks Janette Taylor Ian G Barr 《Euro surveillance : bulletin européen sur les maladies transmissibles = European communicable disease bulletin》2020,25(47)
108.
109.
Steven J. McElroy Shannon L. Castle Jessica K. Bernard Dana Almohazey Catherine J. Hunter Brandon A. Bell Denise Al Alam Larry Wang Henri R. Ford Mark R. Frey 《The American journal of pathology》2014,184(10):2768-2778
Necrotizing enterocolitis (NEC) affects up to 10% of premature infants, has a mortality of 30%, and can leave surviving patients with significant morbidity. Neuregulin-4 (NRG4) is an ErbB4-specific ligand that promotes epithelial cell survival. Thus, this pathway could be protective in diseases such as NEC, in which epithelial cell death is a major pathologic feature. We sought to determine whether NRG4-ErbB4 signaling is protective in experimental NEC. NRG4 was used i) in the newborn rat formula feeding/hypoxia model; ii) in a recently developed model in which 14- to 16-day-old mice are injected with dithizone to induce Paneth cell loss, followed by Klebsiella pneumoniae infection to induce intestinal injury; and iii) in bacterially infected IEC-6 cells in vitro. NRG4 reduced NEC incidence and severity in the formula feed/hypoxia rat model. It also reduced Paneth cell ablation–induced NEC and prevented dithizone-induced Paneth cell loss in mice. In vitro, cultured ErbB4−/− ileal epithelial enteroids had reduced Paneth cell markers and were highly sensitive to inflammatory cytokines. Furthermore, NRG4 blocked, through a Src-dependent pathway, Cronobacter muytjensii–induced IEC-6 cell apoptosis. The potential clinical relevance of these findings was demonstrated by the observation that NRG4 and its receptor ErbB4 are present in human breast milk and developing human intestine, respectively. Thus, NRG4-ErbB4 signaling may be a novel pathway for therapeutic intervention or prevention in NEC.Necrotizing enterocolitis (NEC) is a devastating intestinal disease primarily affecting premature infants. In the United States, NEC afflicts 7% of infants weighing <1500 g.1 In addition to prematurity, risk factors include hypoxia, bacterial colonization of the intestine, and formula feeding.2 The development of NEC seems to be multifactorial, and patients may have any combination of risk factors at the time of presentation. The current disease model is that the immature gut barrier, along with defects in endogenous antimicrobial activity,3 allows bacterial translocation across the epithelium, triggering an inflammatory response that further worsens gut barrier function. Pathogenic bacteria,4, 5 inflammatory cytokines such as tumor necrosis factor (TNF),6, 7, 8 and Paneth cell dropout3 have all been associated with human NEC and contribute to NEC-like injury in animal models.Available therapy for either prevention or treatment of NEC is limited, and patients currently face a mortality rate of approximately 30%.9, 10, 11 Breast-fed infants have a lower risk of NEC than their formula-fed peers,12, 13 and a variety of studies have attempted to identify and characterize factors in human milk that confer this protection. Candidate protective molecules to date include immunoglobulins, oligosaccharides, lactoferrin, and soluble growth factors, such as epidermal growth factor (EGF)14 and heparin-binding EGF-like growth factor (HB-EGF).15 In rat and mouse models, enteral administration of either EGF16, 17 or HB-EGF18 decreases the incidence and severity of NEC. The primary receptor for both EGF and HB-EGF is EGF receptor (EGFR), the prototypic member of the ErbB receptor tyrosine kinase family. However, HB-EGF also activates ErbB4, a member of the ErbB family whose potential role in the developing gut and NEC is not known.ErbB4 has unique biochemical properties distinguishing it from other ErbB family members. Compared with EGFR, ErbB2, or ErbB3, it recognizes a broader collection of ligands, including the EGF-like growth factors HB-EGF and betacellulin as well as the heregulin/neuregulin molecules.19 At the same time, the ErbB4 c-terminus contains a distinct and somewhat restricted set of functional docking sites for downstream effectors20 and is thus predicted to elicit divergent cellular effects on activation versus other family members. In fact, we recently demonstrated that neuregulin-4 (NRG4), an ErbB4-specific ligand that does not bind or activate other family members, including EGFR,21 specifically promotes survival but not migration or proliferation of mouse colon epithelial cells.22 Thus, ErbB4 is a potentially unique and selective target for therapeutic protection in diseases in which intestinal epithelial cell death is a major pathologic feature.We previously reported that ErbB4 is up-regulated in adult human and murine colon inflammation in vivo23 and that ErbB4 overexpression protects cultured colonocytes from cytokine-induced apoptosis in a ligand-dependent manner.24 Furthermore, i.p. NRG4 administration reduces the severity of acute murine dextran sulfate sodium colitis.22 Thus, it seems that ErbB4 induction is a natural compensatory response meant to preserve the epithelium rather than part of disease pathology and that ErbB4 activation with exogenous ligand is protective against induced inflammation. However, the role of this signaling pathway in the small intestine, or during development, has not been described. We hypothesized that ErbB4 and its ligands have a protective role in the small bowel during postnatal development, particularly in the setting of NEC-associated acute injury and inflammation. To advance our understanding of ErbB4 biology in intestinal homeostasis and disease, we tested the hypothesis that NRG4-ErbB4 signaling is protective in experimental NEC. 相似文献
110.
Muhammet U. Kahveci Christine Mangold Holger Frey Yusuf Yagci 《Macromolecular chemistry and physics.》2014,215(6):566-571
A novel polymerization mechanism transformation strategy, involving anionic ring‐opening polymerization and photoinduced cationic polymerization, is successfully applied for the synthesis of poly(ethylene oxide)‐graft‐poly(isobutyl vinyl ether) (PEO‐g‐PIBVE). First, poly(ethylene oxide‐co‐ethoxyl vinyl glycidyl ether) [P(EO‐co‐EVGE)] is synthesized by living anionic polymerization. The vinyl moieties of the functional PEO‐based polymer are converted to the hydrogen iodide adduct by photolysis of diphenyliodonium iodide, monitored using NMR spectroscopy. A modified mode of Lewis acid‐catalyzed living cationic polymerization is performed as a “grafting from” method to generate PIBVE segments grafted onto the PEO main chain. Both the intermediates and the final graft copolymers are characterized by gel‐permeation chromatography (GPC) and 1H NMR analysis.